Bedfordshire, Luton and Milton Keynes Area Prescribing Committee

Ref: APC Bulletin 3
Bulletin Date: 21/06/22
Review Date: March 2024


Lipid Management for Primary and Secondary Prevention of Cardiovascular Disease (CVD)

APC Recommendations:

Updated Bulletin (March 2022) 

Lipid management for Primary and Secondary prevention of CVD

To support the delivery of the NHS Long Term Plan,  the Accelerated Access Collaborative (AAC) Lipid Management Rapid Uptake Product (RUP) Working Group has developed a NICE-endorsed clinical pathway for the management of lipids in primary and secondary prevention of CVD.

The pathway has been updated by the AAC to include Inclisiran▼ (Leqvio®) following the release of its positive NICE TA for treating primary hypercholesterolaemia or mixed dyslipidaemia.

The APC committee agreed to ratify the updated pathway  and work on the local implementation of the pathway is ongoing.

Click here

https://www.england.nhs.uk/aac/wp-content/uploads/sites/50/2020/04/lipid-management-pathway-v6.pdf

Please use the search box to search the whole site if you can't find what you're looking for:

To top
Welcome to the BLMK Medicines Optimisation website.
This site is currently being updated.

If you have any feedback or find any issues, please email the team:
BLMKICB.MedsOpt@nhs.net